USP7 and neoplasm: Deletion of USP7 in cancer cell lines and organoids inhibits WNT activation by restoring β-catenin ubiquitination specifically in APC-mutated, but not wild-type (WT), cells, suggesting that USP7 may represent a tumor-specific drug target.